

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Block Listing Return

Name of <i>applicant</i> :	Oncimmune Holdings plc			
Name of scheme:	Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans			
Period of return:	From:	13/03/24	To:	11/02/25
Balance of unallotted securities under scheme(s) from previous return:	5,678,464			
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0			
<u>Less:</u> Number of <i>securities</i> issued/allotted under scheme(s) during period (see UKLR 20.6.7G):	0			
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:	5,678,464			

For further information:
contact@oncimmune.com

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist Sales)
Ondraya Swanson (Corporate Broking)
+44 (0) 20 7220 0500

Zeus (Joint Broker)
Dominic King
+44 (0)20 3829 5000

About Oncimmune

Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

For more information, visit www.oncimmune.com

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lse.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLRTBMPTMTIBBRA